D-Pharm Management & BOD May 2010.doc

oculoplaniaballtownBiotechnology

Dec 1, 2012 (4 years and 6 months ago)

248 views


D
-
PHARM LTD.

Kiryat Weizmann Science Park, Bldg. 7

P.O.Box 2313 , Rehovot 76123 Israel

Tel: 972
-
8
-
9385100

Fax: 972
-
8
-
9300795

www.dpharm.com







May

20
10



MANAGEMENT:


Alexander Kozak, Ph.D.,
President

and
Chief Executive Officer

Gilad Rosenberg, MD,

VP Clinical Development

Ofra Yamin,
VP

Finance and Human Resources

Peter Geffen,
Director of
Quality Assurance and Re
gulatory Affairs



CHAIRMAN OF BOARD OF DIRECTORS
:

Ruben Krupik
,

Clal Biotechnology

Industries
,

Ar
te Venture Group



DIRECTORS:

Dr. Aharon Schwartz,
Teva Pharmaceutical Industries Ltd

Ofer Goldberg,
Clal Biotechnology

Industries




EXTERNAL DIRECTOR
S:

Gil

Bianco, formerly with Agis Industries

Osnat Ronen,
Viola Private Equity

and

formerly with Bank Leumi


Dr. Avi Molcho
,
Forbion Capital Partners

Prof. Ron Kenett
, KPA Group













D
-
Pharm
-

Management Team


Alex Kozak Ph.D.

President, Chief
Executive Officer


Dr. Kozak, the company's founder, has been President and CEO since its inception in 1993. He is the
inventor of D
-
Pharm's core technology. He holds a Ph.D. degree in neurochemistry from the Weizmann
Institute of Science, Israel (1992). D
r. Kozak serves on the Board of Directors of several Israeli start
-
up
companies. Dr. Kozak is a member of the Society for Neurosciences, the Society for Neurochemistry,
LES and the New York Academy of Sciences.



Gilad Rosenberg

VP Clinical Development


D
r
.

Rosenberg joined the Company in 2000. Prior to joining the Company Dr. Rosenberg was Medical

Director for Merck, Sharp and Dohme's Israeli subsidiary. He graduated

cum laude from the Rappaport
Faculty of Medicine of the Technion, Israel

Institute of Tec
hnology in 1992, and received post
-
graduate
training at

Hadassah Medical Center, Jerusalem, in neurology and at Oxford University

in Neuroscience.



Ofra Yamin

VP
Finance

and

Human Resources


Ms. Yamin joined the Company in May 1996 as Controller and Hea
d of the Accounting Department. Pr
ior

to that, she owned her own firm, providing accounting services to high tech and commercial businesses.
She received a B.Sc. in Economics and Accounting from the Hebrew University in Jerusalem in 1984,
and her MBA from

the University of Tel Aviv in 2001. She qualified as a C.P.A. and was certified
accountant by the Israel Ministry of Law in 1987.



Peter Gef
f
en

Director of
Quality Assurance and Regulatory Affairs


Mr
.

Geffen joined the Company in 1999. He was previousl
y a director, (Analytical R&D) at Taro
Pharmaceuticals and Quality Control Manager at Neoprobe Ltd. He received a B.Sc. (Hons) in Biology
from the University of London in 1976.




Ruben Krupik

Chairman of the Board of Directors


Mr
.

Krupik joined
D
-
Pharm's

Board in 2003

and became Chairman in 2006
.

He is

CEO of Clal Biotech
Industries (CBI), the largest investor in life sciences in Israel

and
founder and
CEO

of ARTE Venture
Group, an investment management firm specializing in business development. He former
ly served as
president and chief executive officer of RDC Rafael Development Corporation, a business development
subsidiary of RAFAEL, a division of the Israel Ministry of Defence. Mr Krupik has a B.A. in Political
Science from the Hebrew University of Jer
usalem and an L.L.B. Faculty of Law degree from Tel
-
Aviv
University.